- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06414434
BTX-A51 in Patients With Liposarcoma
A Pilot Study of BTX-A51 in Patients With Metastatic and/or Recurrent Liposarcomas Characterized by MDM2 Amplifications
This study is testing if the recommended dose of BTX-A51 is safe and tolerable in participants with liposarcoma.
The name of the study drug used in this research study is:
-BTX-A51 (a type of kinase inhibitor)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a single arm, pilot study assessing the safety and preliminary exploration of BTX-A51 in participants with metastatic and/or recurrent liposarcomas characterized by Murine Double Minute Clone 2 (MDM2) amplifications. BTX-A51 works in a different way from currently approved therapies used to treat liposarcoma by blocking proteins called CK1α and CDK9.
The U.S. Food and Drug Administration (FDA) has not approved BTX-A51 as a treatment for Liposarcoma.
The research study procedures include screening for eligibility, Computerized Tomography (CT) scans, Magnetic Resonance Imaging (MRI) scans, or Positron Emission Tomography (PET) scans, blood tests, and tumor biopsies.
Participants will receive study treatment for as long as there are no serious side effects, and disease does not get worse. Participants will be followed for 1 year after the last dose of BTX-A51.
It is expected that about 12 people will take part in this research study.
Edgewood Oncology is supporting this research study by providing the study drug.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Michael Wagner, MD
- Phone Number: 617-632-5204
- Email: MICHAEL_WAGNER@DFCI.HARVARD.EDU
Study Contact Backup
- Name: Michael Wagner, MD
- Phone Number: 617-632-3352
- Email: michael_wagner@dfci.harvard.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana-Farber Cancer Institute
-
Principal Investigator:
- Michael Wagner, MD
-
Contact:
- Michael Wagner, MD
- Phone Number: 617-632-3352
- Email: michael_wagner@dfci.harvard.edu
-
Boston, Massachusetts, United States, 02215
- Brigham and Women's Hospital
-
Principal Investigator:
- Michael Wagner, MD
-
Contact:
- Michael Wagner, MD
- Phone Number: 617-632-3352
- Email: michael_wagner@dfci.harvard.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Study participants must have histologically-confirmed metastatic and/or recurrent liposarcoma (limited to the subtypes of well-differentiated and/or dedifferentiated liposarcoma, which are associated with MDM2 amplifications).
- ECOG performance status ≤2
Adequate organ and marrow function as defined by the following metrics resulted within 7 days of study enrollment:
- WBC >3000/mm3
- Platelets >75,000μl
- ANC >1500μl
- Hgb >9g/dl
- Creatinine <1.5 x ULN or measured CrCl of >60ml/m2/1.73 m2
- Total bilirubin <2 x ULN
- AST/ALT <3 x ULN
Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non- nodal lesions and short axis for nodal lesions) as ≥20 mm (≥2 cm) by chest x-ray or as
≥10 mm (≥1 cm) with CT scan, MRI, or calipers by clinical exam. See Section 11 (Measurement of Effect) for the evaluation of measurable disease.
- Patients must have recovered from toxicity related to prior therapy to grade <=1 (defined by CTCAE v5.0) (except alopecia and neuropathy, or immunotherapy related hypothyroidism)
- As the effect of this study drug on the developing human fetus is not known, women of child-bearing potential and men must agree to use at least 2 methods of contraception (abstinence; hormonal or barrier method of birth control) for the study and at least 2 months after completion.
- Female patient of childbearing potential has a negative serum pregnancy test within 7 days of study enrollment.
- Ability to understand and the willingness to sign a written informed consent document.
- Age ≥18 years
- Patients must have completed all prior anti-cancer treatment for liposarcoma, including radiation, ≥ 14 days prior to registration.
Exclusion Criteria:
- Patient with current evidence of active and uncontrolled infection, NYHA Class III-IV CHF, documented Child's class B-C cirrhosis, or uncontrolled medical disease which in the opinion of the investigator or the sponsor could compromise safety and/or assessment of efficacy.
- Active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV); subjects who are positive for hepatitis B core antibody, hepatitis B surface antigen, or hepatitis C antibody must have a negative PCR result before enrollment; those who are PCR positive will be excluded.
- Major surgical procedure or open surgical biopsy within 28 days of first dose of study drug
- Active central nervous system (CNS) disease involvement, or prior history of NCI CTCAE Grade ≥3 drug-related CNS toxicity. Subject with known CNS metastases that are treated and stable (without evidence of CNS toxicity) and are not requiring systemic steroids are allowed to be enrolled.
- Patient has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
- Myocardial infarction within 12 months of screening
- Use of any other concurrent investigational agents or anticancer agents, excluding hormonal therapy for breast or prostate cancer
- Pregnant women are excluded from this study because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with BTX- A51, breastfeeding should be discontinued if the mother is treated with BTX-A51.
- Inability to swallow pills or inadequate GI absorption in the opinion of the treating investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BTX-A51
Participants will be enrolled and will complete study procedures as follows:
|
Multi-kinase inhibitor, 1.0 mg, 2.0 mg, and 7.0 mg immediate-release capsules, taken orally per protocol.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with adverse events, with laboratory abnormalities, with dose modifications, delays, interruptions, or premature discontinuation of BTX-A51 due to an adverse event
Time Frame: All AEs will be recorded from the time the subject signs informed consent until 30 days after the last dose of study BTX-A51.
|
Safety and tolerability will be monitored through continuous reporting of treatment-emergent and treatment-related adverse events, laboratory abnormalities, and incidence of subjects experiencing dose modifications, delays, interruptions, or premature discontinuation of BTX-A51 due to an adverse event.
Toxicities are to be assessed according to the CTCAEv5.
|
All AEs will be recorded from the time the subject signs informed consent until 30 days after the last dose of study BTX-A51.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1-year Progression-Free Survival (PFS) Rate
Time Frame: 1 year
|
1-year PFS is a probability estimated using progression-free survival based on the Kaplan-Meier method is defined as the duration between randomization and documented disease progression (PD) or death, or is censored at time of last disease assessment.
|
1 year
|
1-year Overall Survival (OS)
Time Frame: 1 year
|
1-year OS is a probability estimated using the Kaplan-Meier method; OS is defined as the time from study entry to death, or censored at date last known alive.
|
1 year
|
Overall Response Rate (ORR)
Time Frame: ORR expected to be observed up to 3 years
|
The overall response rate (ORR) was defined as the proportion of participants achieving complete response (CR) or partial response (PR) based on RECISTv1.1 criteria.
|
ORR expected to be observed up to 3 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Michael Wagner, MD, Dana-Farber Cancer Institute
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 24-156
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liposarcoma
-
Mario Negri Institute for Pharmacological ResearchFondazione IRCCS Istituto Nazionale dei Tumori, Milano; Humanitas Hospital,...RecruitingLiposarcoma, Myxoid | Liposarcoma, Dedifferentiated | Liposarcoma, Round CellItaly
-
GlaxoSmithKlineCompleted
-
Memorial Sloan Kettering Cancer CenterRecruitingSarcoma | Soft Tissue Sarcoma | Sarcoma,Soft Tissue | Dedifferentiated Liposarcoma | Recurrent Dedifferentiated Liposarcoma | Metastatic Dedifferentiated Liposarcoma | Unresectable Dedifferentiated LiposarcomaUnited States
-
Johnson & Johnson Pharmaceutical Research & Development...PharmaMarCompletedLiposarcoma,MyxoidFrance, United States, Germany
-
The Netherlands Cancer InstituteUnknownMyxoid Liposarcoma of Soft TissueNetherlands, United Kingdom, Norway, United States, Denmark
-
Maria Sklodowska-Curie National Research Institute...Active, not recruiting
-
The Netherlands Cancer InstituteM.D. Anderson Cancer Center; Mayo Clinic; Radboud University Medical Center; Aarhus... and other collaboratorsRecruitingMyxoid LiposarcomaNetherlands
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); Daiichi Sankyo, Inc.Completed
-
Systems Medicine LLCUnknown
-
GlaxoSmithKlineTerminatedNeoplasmsUnited States, Germany, Netherlands, Canada, Australia, Sweden
Clinical Trials on BTX-A51
-
Edgewood Oncology Inc.RecruitingMetastatic Breast Cancer | Advanced Solid TumorUnited States
-
Edgewood Oncology Inc.RecruitingAcute Myeloid Leukemia | Myelodysplastic SyndromeUnited States
-
AJU Pharm Co., Ltd.CompletedType2 DiabetesKorea, Republic of
-
BioTheryX, Inc.TerminatedAcute Myeloid Leukemia | Non Hodgkin Lymphoma | Advanced Solid TumorUnited States
-
Botanix PharmaceuticalsCompletedAtopic DermatitisUnited States, Australia, New Zealand
-
AJU Pharm Co., Ltd.CompletedDiabetes Mellitus, Type 2Korea, Republic of
-
Botanix PharmaceuticalsCompletedAcne VulgarisUnited States, Australia
-
Allan Vestergaard Danielsen, MDNot yet recruitingPain, Postoperative | Chronic Pain | Pain, Neuropathic | Post-thoracotomy Pain SyndromeDenmark
-
UroGen Pharma Ltd.CompletedInterstitial Cystitis | ICIsrael
-
The University of Texas Health Science Center,...University of HoustonCompleted